QQ客服 官方微博 反馈留言

	Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial
	Yuan, Jinyi; Mo, Biwen; Ma, Zhuang; Lv, Yuan; Cheng, Shih-Lung; Yang, Yanping; Tong, Zhaohui; Wu, Renguang; Sun, Shenghua; Cao, Zhaolong
	2019
卷号	52期号:1页码:35-44
关键词	Clinical outcome Community-acquired pneumonia Levofloxacin Nemonoxacin Randomized controlled trial Safety
ISSN号	1684-1182
DOI	10.1016/j.jmii.2017.07.011
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6344491
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yuan, Jinyi,Mo, Biwen,Ma, Zhuang,et al. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial[J],2019,52(1):35-44.
APA	Yuan, Jinyi.,Mo, Biwen.,Ma, Zhuang.,Lv, Yuan.,Cheng, Shih-Lung.,...&Su, Wei-Juin.(2019).Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.,52(1),35-44.
MLA	Yuan, Jinyi,et al."Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial".52.1(2019):35-44.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。